At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 34 enrolled
Drug / intervention
R788 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III Study in Patients With Chronic Idiopathic Thrombocytopenic Purpura in R788
In Brief
A Phase 3 clinical trial evaluating R788 and Placebo for Idiopathic Thrombocytopenic Purpura. Completed, enrolled 34 participants across 1 site.
Detailed Summary
The purpose of this study is to investigate the efficacy, safety and pharmacokinetics of R788 compared with placebo, and to investigate the safety and efficacy of long term dosing of R788 in patients with chronic idiopathic thrombocytopenic purpura.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIdiopathic Thrombocytopenic Purpura
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
2020202120222023202420252026
First PostedOct 2019
Enrollment StartDec 2019
Primary CompletionDec 2021
Study CompletionSep 2023
TodayJul 2026
First PostedOct 18, 2019
Enrollment StartDec 24, 2019
Primary CompletionDec 21, 2021
Study CompletionSep 25, 2023
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 6.7 years ago
Interventions
R788drug
Oral administration
Placebodrug
Oral administration